Show simple item record

dc.contributor.advisorMichael Leeen_US
dc.contributor.authorFontana, Rachel
dc.date.accessioned2023-03-15T19:29:45Z
dc.date.available2023-03-15T19:29:45Z
dc.date.issued2023-02-23
dc.identifier.doi10.13028/dmby-d122en_US
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51826
dc.description.abstractRegulated cell death (RCD) is composed of several pathways that control cell fate. While each pathway is mechanistically distinct, these pathways have been shown to interact. Most of these interactions tend to be antagonistic, such that activation of one pathway blocks the subsequent activation of another pathway. This highlights that death pathways tend to be mutually exclusive. Thus, combining two cytotoxic drugs that activate different death pathways could result in less cell death than predicted, hampering therapeutic efficacy. As such, it is necessary to characterize which death pathways are activated by clinically relevant drugs, particularly for drug combination studies. However, studies of death pathway engagement are complicated by the fact that many drugs are capable of activating multiple RCD pathways. In order to improve annotations of RCD pathway activation by specific stimuli, we need to learn what features dictate which death pathway is activated. To study this phenomenon, we focused on characterizing RCD execution after treatment with methylnitronitrosoguanidine (MNNG), a DNA alkylating agent. MNNG is the canonical activator of parthanatos, an inflammatory form of RCD dependent on PARP-1 hyper-activation. We found that MNNG exhibits dose-dependent changes in death features, such as death onset time and death rate, indicative of a death mechanism change. As such we hypothesized that MNNG can induce multiple RCD pathways in a dose-dependent fashion. We found that this dose-dependent change in death features was generalizable to multiple cell lines. Moreover, we established that the phenotype was not due to PARP-trapping effects. Importantly, we uncovered that MNNG does induce a death mechanism switch. We found that MNNG is capable of inducing either parthanatos or apoptosis, depending on the dose. We also found evidence that the two death pathways induced by MNNG were mutually exclusive. And lastly, we established that the death mechanism switch was not due to altered mismatch repair (MMR). The information from this study could help to shed light on clinical outcomes from drug combination trials, specifically combinations with DNA damaging agents and PARP inhibitors.en_US
dc.language.isoen_USen_US
dc.publisherUMass Chan Medical Schoolen_US
dc.rightsCopyright © 2023 Fontanaen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.subjectRCDen_US
dc.subjectRegulated Cell Deathen_US
dc.subjectMNNGen_US
dc.subjectmethylnitronitrosoguanidineen_US
dc.subjectPolypharmacologyen_US
dc.subjectPARP-1en_US
dc.subjectParthanatosen_US
dc.subjectApoptosisen_US
dc.titleExploring the Phenomenon of MNNG Dose-Dependent Death Polypharmacologyen_US
dc.typeMaster's Thesisen_US
atmire.contributor.authoremailfontana.r@northeastern.eduen_US
dc.contributor.departmentMorningside Graduate School of Biomedical Sciencesen_US
dc.contributor.departmentProgram in Bioinformatics and Integrative Biologyen_US
dc.contributor.departmentSystems Biologyen_US
dc.description.thesisprogramBioinformatics and Computational Biologyen_US
dc.identifier.orcid0000-0001-9363-8991en_US


Files in this item

Thumbnail
Name:
Fontana_MS_Thesis_FINAL_EDITED.pdf
Embargo:
2025-03-15
Size:
3.043Mb
Format:
PDF
Description:
MS Thesis

This item appears in the following Collection(s)

Show simple item record

Copyright © 2023 Fontana
Except where otherwise noted, this item's license is described as Copyright © 2023 Fontana